As several natural agent TRAIL agonists are currently under clinical development, these results in human myeloid leukemia cell lines and primary PBMCs provide a rationale for testing the combination of Med and TRAIL agonists in management of myeloid leukemia. The gene discussed is TNFSF10; the disease is myeloid leukemia.